Profile data is unavailable for this security.
About the company
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company. The Company is focused on developing and commercializing treatments for skin diseases. Its product pipeline consists of three product candidates: YCANTH, VP-315 and VP-103. YCANTH is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. We are also developing YCANTH for potential follow-on indications for the treatment of common warts and external genital warts. In addition, the Company is also developing YCANTH for the treatment of external genital warts, or external genital warts EGW. Its second candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma, non-metastatic melanoma, and non-metastatic Merkel cell carcinoma. VP-103, a second cantharidin based drug device combination for the potential treatment of plantar warts.
- Revenue in USD (TTM)5.12m
- Net income in USD-67.00m
- Incorporated2013
- Employees100.00
- LocationVerrica Pharmaceuticals Inc10 N High St Ste 200WEST CHESTER 19380-3014United StatesUSA
- Phone+1 (484) 453-3300
- Fax+1 (302) 636-5454
- Websitehttps://verrica.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erasca Inc | 0.00 | -126.86m | 320.71m | 126.00 | -- | 0.9702 | -- | -- | -0.8423 | -0.8423 | 0.00 | 1.91 | 0.00 | -- | -- | 0.00 | -30.29 | -- | -32.45 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 48.50 | -- | -- | -- |
| Jasper Therapeutics Inc | 0.00 | -64.47m | 321.77m | 45.00 | -- | 3.04 | -- | -- | -6.19 | -6.19 | 0.00 | 7.03 | 0.00 | -- | -- | 0.00 | -90.00 | -- | -104.13 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -71.06 | -- | -- | -- |
| Anavex Life Sciences Corp | 0.00 | -43.16m | 322.48m | 40.00 | -- | 2.31 | -- | -- | -0.5357 | -0.5357 | 0.00 | 1.65 | 0.00 | -- | -- | 0.00 | -29.12 | -40.04 | -31.88 | -43.97 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 0.9857 | -- | -- | -- |
| Nektar Therapeutics | 90.17m | -175.84m | 323.18m | 137.00 | -- | 2.55 | -- | 3.58 | -0.9195 | -0.9195 | 0.4709 | 0.69 | 0.1883 | 1.93 | 27.27 | 658,153.30 | -36.72 | -31.02 | -41.60 | -34.63 | 60.91 | 78.04 | -195.02 | -372.21 | 5.79 | -24.95 | 0.00 | -- | -2.10 | -40.35 | 25.03 | -- | -42.89 | -- |
| Q32 Bio Inc | 1.16m | -112.96m | 323.65m | 7.00 | -- | 1.20 | -- | 279.97 | -35.17 | -35.17 | 0.3598 | 22.64 | 0.0074 | -- | -- | 165,142.90 | -55.64 | -34.98 | -62.45 | -37.92 | -- | -- | -7,532.87 | -971.76 | -- | -- | 0.00 | -- | -63.97 | -26.32 | -2,156.96 | -- | -60.90 | -- |
| MeiraGTx Holdings PLC | 11.38m | -74.11m | 326.03m | 402.00 | -- | 2.68 | -- | 28.65 | -1.27 | -1.27 | 0.1887 | 1.89 | 0.0381 | -- | 0.4821 | 27,159.90 | -24.81 | -26.40 | -31.62 | -32.66 | -- | -- | -651.19 | -420.70 | -- | -27.54 | 0.3729 | -- | -11.95 | -- | 35.17 | -- | 12.37 | -- |
| Atea Pharmaceuticals Inc | 0.00 | -135.96m | 327.63m | 75.00 | -- | 0.5846 | -- | -- | -1.63 | -1.63 | 0.00 | 6.65 | 0.00 | -- | -- | 0.00 | -21.55 | -5.90 | -22.46 | -6.98 | -- | -- | -- | -38.91 | -- | -- | 0.00 | -- | -- | -- | -17.30 | -- | -- | -- |
| Tenaya Therapeutics Inc | 0.00 | -124.08m | 329.77m | 140.00 | -- | 2.06 | -- | -- | -1.68 | -1.68 | 0.00 | 2.04 | 0.00 | -- | -- | 0.00 | -55.21 | -- | -61.66 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.3388 | -- | -- | -- |
| Mersana Therapeutics Inc | 38.30m | -134.81m | 331.60m | 123.00 | -- | 11.85 | -- | 8.66 | -1.14 | -1.14 | 0.3203 | 0.2287 | 0.1549 | -- | -- | 311,365.80 | -54.52 | -61.68 | -75.37 | -81.35 | -- | -- | -352.01 | -622.19 | -- | -- | 0.4749 | -- | 38.65 | 28.32 | 15.94 | -- | 9.61 | -- |
| Sutro Biopharma Inc | 153.73m | -106.79m | 339.32m | 302.00 | -- | 1.69 | -- | 2.21 | -1.79 | -1.79 | 2.56 | 2.45 | 0.3503 | -- | 7.12 | 509,043.00 | -24.34 | -25.48 | -29.77 | -29.75 | -- | -- | -69.47 | -113.71 | -- | -- | 0.0264 | -- | 126.84 | 31.96 | 10.41 | -- | 22.61 | -- |
| Verrica Pharmaceuticals Inc | 5.12m | -67.00m | 339.36m | 100.00 | -- | 17.17 | -- | 66.23 | -1.46 | -1.46 | 0.113 | 0.466 | 0.0811 | -- | 2.09 | 51,240.00 | -106.07 | -55.75 | -126.60 | -78.33 | 85.44 | -- | -1,307.48 | -754.94 | 4.49 | -51.74 | 0.6914 | -- | -43.27 | -- | -173.59 | -- | 5.65 | -- |
| Nautilus Biotechnology Inc | 0.00 | -67.44m | 343.23m | 163.00 | -- | 1.38 | -- | -- | -0.5402 | -0.5402 | 0.00 | 1.99 | 0.00 | -- | -- | 0.00 | -21.26 | -- | -21.85 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.93 | -- | -- | -- |
| Black Diamond Therapeutics Inc | 0.00 | -82.44m | 343.70m | 54.00 | -- | 2.70 | -- | -- | -1.92 | -1.92 | 0.00 | 2.26 | 0.00 | -- | -- | 0.00 | -52.37 | -40.29 | -58.91 | -43.29 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 9.57 | -- | -15.37 | -- |
| Revance Therapeutics Inc | 236.65m | -313.72m | 346.00m | 534.00 | -- | -- | -- | 1.46 | -3.61 | -3.65 | 2.71 | -0.945 | 0.4482 | 1.87 | 10.46 | -- | -59.42 | -55.55 | -69.02 | -63.20 | 69.11 | -- | -132.57 | -304.96 | 4.64 | -30.79 | 1.30 | -- | 76.55 | 128.84 | 9.10 | -- | -0.3022 | -- |
| Amarin Corporation plc (ADR) | 277.46m | -52.61m | 350.27m | 275.00 | -- | 0.6414 | -- | 1.26 | -0.1288 | -0.1288 | 0.679 | 1.33 | 0.3363 | 0.4197 | 2.23 | 1,008,927.00 | -6.38 | -4.48 | -8.90 | -6.54 | 63.61 | 75.70 | -18.96 | -8.59 | 1.93 | -- | 0.00 | -- | -16.87 | 6.01 | 44.13 | -- | 55.83 | -- |
Data as of May 10 2024. Currency figures normalised to Verrica Pharmaceuticals Inc's reporting currency: US Dollar USD
38.17%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Perceptive Advisors LLCas of 31 Dec 2023 | 7.10m | 16.74% |
| Avoro Capital Advisor LLCas of 31 Dec 2023 | 4.00m | 9.43% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 1.51m | 3.56% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 1.23m | 2.89% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 1.01m | 2.38% |
| Geode Capital Management LLCas of 31 Dec 2023 | 429.68k | 1.01% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 389.27k | 0.92% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 2023 | 198.88k | 0.47% |
| BML Capital Management LLCas of 31 Mar 2024 | 180.00k | 0.42% |
| MML Investors Services LLCas of 31 Dec 2023 | 147.55k | 0.35% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
